Trial Profile
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Favezelimab (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Gastric cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Merck Sharp & Dohme Corp.
- 08 Mar 2024 Planned End Date changed from 8 Apr 2024 to 15 Mar 2024.
- 08 Mar 2024 Planned primary completion date changed from 8 Apr 2024 to 15 Mar 2024.
- 31 Jan 2024 Planned End Date changed from 26 Feb 2024 to 8 Apr 2024.